A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

NCT03447262 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

484

Enrollment

INDUSTRY

Sponsor class

Stopped At Sponsor's Discretion

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-659/TEZ/IVA
DRUG: IVA

Sponsor

Vertex Pharmaceuticals Incorporated